End-point interpretation in clinical trials: The case for discipline

Controlled Clinical Trials

Volumn 20, Issue 1, 1999, Pages 40-49

  Moyé, Lemuel A ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Alpha allocation; End point reporting; Physician scientist responsibility; Prospective end points

Indexed keywords

BISOPROLOL; CARVEDILOL;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DATA ANALYSIS; DRUG APPROVAL; ERROR; FOOD AND DRUG ADMINISTRATION; HUMAN; MORTALITY; POLICY; PUBLICATION; RESPONSIBILITY;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; DRUG APPROVAL; HEART FAILURE, CONGESTIVE; HUMANS; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS; UNITED STATES;

EID: 0032972732     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(98)00051-8     Document Type: Article

References (11)

1. Waagstein F., Hjalmarson A., Varnauskass E.et al. Effect of chronic beta adrenergic receptor blockage in congestive cardiomyopathy. Br Heart J. 37:1975;205-211.
2. Waagstein F., Bristow M.R., Swedberg K.et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
3. CIBIS Investigators and Committees A randomized trial of beta-blockade in heart failure. the Cardiac Insufficiency Bisoprolol Study (CIBIS) Circulation. 90:1994;1765-1773.
4. Packer M., Bristow M.R., Cohn J.N.et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
5. Fisher L. Carvedilol and the FDA approval process. the FDA paradigm and reflections upon hypotheses testing Controlled Clin Trials. 20:1999;16-39.
6. Lewis J.A. Statistical issues in the regulation of medicines. Stat Med. 14:1995;127-136.
7. Pocock S.J., Geller N.L., Tsiatis A.A. The analysis of multiple endpoints in clinical trials. Biometrics. 43:1987;487-498.
8. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
9. Pfeffer M.A., Braunwald E., Moyé L.A.et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 327:1993;669-677.
10. Friedman L., Furberg C., DeMets D. Fundamentals of Clinical Trials. 3:1996;Mosby, St. Louis.
11. Moyé L.A. P-value interpretation and alpha allocation in clinical trials. Ann Epidemiol. 8:1998;351-357.